Celgene Co. (NASDAQ:CELG) – Research analysts at SunTrust boosted their Q2 2016 earnings per share estimates for shares of Celgene in a research report issued to clients and investors on Thursday, Zacks Investment Research reports. SunTrust analyst Y. Suneja now expects that the firm will post earnings per share of $1.20 for the quarter, up from their prior estimate of $1.18. SunTrust has a “Buy” rating and a $145.00 price objective on the stock. The consensus estimate for Celgene’s Q2 2016 earnings is $1.15 per share. SunTrust also issued estimates for Celgene’s FY2020 earnings at $12.14 EPS.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, January 28th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by $0.04. The company had revenue of $2.54 billion for the quarter, compared to analyst estimates of $2.54 billion. The business’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.01 EPS.

Other analysts have also recently issued research reports about the stock. William Blair restated an “outperform” rating on shares of Celgene in a report on Monday. Piper Jaffray restated an “overweight” rating and set a $163.00 target price on shares of Celgene in a report on Monday. Bank of America restated a “buy” rating and set a $125.00 target price (down previously from $146.00) on shares of Celgene in a report on Saturday. Barclays dropped their target price on shares of Celgene from $130.00 to $120.00 and set an “equal weight” rating on the stock in a report on Saturday. Finally, Cantor Fitzgerald restated a “buy” rating and set a $163.00 target price on shares of Celgene in a report on Friday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-two have given a buy rating and three have given a strong buy rating to the company’s stock. Celgene currently has an average rating of “Buy” and a consensus price target of $147.62.

Celgene (NASDAQ:CELG) traded down 2.12% during mid-day trading on Monday, reaching $98.66. 2,262,584 shares of the company were exchanged. Celgene has a one year low of $92.98 and a one year high of $140.72. The company has a market capitalization of $77.51 billion and a PE ratio of 50.86. The stock has a 50-day moving average price of $110.27 and a 200 day moving average price of $117.81.

Several hedge funds and institutional investors have recently bought and sold shares of CELG. Beacon Capital Management purchased a new position in Celgene during the fourth quarter worth approximately $0. Capital Investment Services of America purchased a new position in Celgene during the fourth quarter worth approximately $207,000. Meristem purchased a new position in Celgene during the fourth quarter worth approximately $262,000. Crestpoint Capital Management purchased a new position in Celgene during the fourth quarter worth approximately $335,000. Finally, Park National increased its position in Celgene by 41.2% in the fourth quarter. Park National now owns 2,805 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 819 shares in the last quarter.

In other news, Director Ernest Mario sold 40,000 shares of the stock in a transaction that occurred on Monday, December 28th. The stock was sold at an average price of $119.36, for a total transaction of $4,774,400.00. Following the completion of the transaction, the director now directly owns 82,449 shares in the company, valued at approximately $9,841,112.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 14,464 shares of the stock in a transaction that occurred on Monday, December 21st. The shares were sold at an average price of $110.62, for a total value of $1,600,007.68. Following the transaction, the director now owns 88,485 shares of the company’s stock, valued at $9,788,210.70. The disclosure for this sale can be found here.

Celgene Corporation (NASDAQ:CELG), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

12 Month Chart for NASDAQ:CELG

Get a free copy of the Zacks research report on Celgene (CELG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.